Sight Sciences reports Q2 EPS (23c), consensus (28c)

Reports Q2 revenue $19.56M, consensus $18.18M. Surgical Glaucoma revenue was $19.23M and Dry Eye revenue was $330K. Surgical Glaucoma ordering accounts increased to an all-time high of 1,174. “Our second-quarter results reflect strong execution and growing momentum, with positive trends including sequential growth in both surgical glaucoma ordering accounts and procedural utilization that mark meaningful progress as we strengthen our position as the market leader in implant-free MIGS,” said Paul Badawi, co-founder and CEO of Sight Sciences (SGHT). “Our focus has been on equipping interventional eyecare providers with innovative technologies that enhance patient outcomes. As we enter the second half of 2025, these developments reinforce our confidence in our ability to deliver long-term value and elevate the standard of care for glaucoma and dry eye disease management.”